• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

跨国结核病参考实验室网络中的药敏试验能力。

Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories.

机构信息

International Union Against Tuberculosis and Lung Disease, Paris, France.

出版信息

Int J Tuberc Lung Dis. 2011 Jan;15(1):116-24.

PMID:21276307
Abstract

SETTING

The network of supranational tuberculosis reference laboratories (SRLs).

OBJECTIVE

To evaluate the annual SRL Rounds 6-14 of proficiency testing for first-line drug susceptibility testing (DST).

DESIGN

Panels consisted of 20-30 cultures (including 10 pairs of duplicate strains), aiming at 50% resistance prevalence with a variety of profiles. The 27 SRLs participating in at least one of these rounds were free to use their preferred DST method. A judicial gold standard of at least 80% concordant 'susceptible' or 'resistant' was used to determine sensitivity, specificity and efficiency; otherwise the strain was excluded.

RESULTS

Of 600 strains, 10% were excluded from evaluation. The average SRL sensitivity and specificity varied between rounds, without attaining significance or trends. Both sensitivity and specificity remained at >95% for isoniazid (INH), rifampicin (RMP) and streptomycin and at >80% for ethambutol. The 16 SRLs participating in all rounds performed consistently better.

CONCLUSION

The rounds succeeded in comparing the proficiency of laboratories, and should be further promoted for DST quality assessment. However, to function with greater precision and to ultimately improve the clinical relevance of DST, the INH and RMP judicial result gold standard also needs to take into account genotypic and treatment outcome information.

摘要

背景

跨国结核病参考实验室网络。

目的

评估第 6 至 14 轮一线药物敏感性检测(DST)的年度 SRL 能力验证。

设计

面板由 20-30 个培养物组成(包括 10 对重复菌株),目标是耐药率为 50%,具有多种耐药模式。至少参加过一轮的 27 个 SRL 可自由选择其首选的 DST 方法。采用至少 80%一致性的“敏感”或“耐药”的司法金标准来确定敏感性、特异性和效率;否则将排除该菌株。

结果

在 600 株菌株中,有 10%被排除在评估之外。各轮次的平均 SRL 敏感性和特异性存在差异,但无统计学意义或趋势。异烟肼(INH)、利福平(RMP)和链霉素的敏感性和特异性均保持在>95%,乙胺丁醇的敏感性和特异性均保持在>80%。所有轮次都参加的 16 个 SRL 表现一致较好。

结论

这些轮次成功地比较了实验室的能力,应该进一步推广用于 DST 质量评估。然而,为了更精确地发挥作用,并最终提高 DST 的临床相关性,INH 和 RMP 的司法结果金标准还需要考虑基因型和治疗结果信息。

相似文献

1
Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories.跨国结核病参考实验室网络中的药敏试验能力。
Int J Tuberc Lung Dis. 2011 Jan;15(1):116-24.
2
External quality assurance of drug susceptibility testing in the southern African development community.南部非洲发展共同体药物敏感性测试的外部质量保证
Int J Tuberc Lung Dis. 2013 Mar;17(3):425. doi: 10.5588/ijtld.12.0856.
3
Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing.世界卫生组织/国际防痨和肺部疾病联盟超国家实验室网络中结核分枝杆菌药敏试验的质量保证计划:第一轮能力验证试验
Int J Tuberc Lung Dis. 1997 Jun;1(3):231-8.
4
Proficiency of drug susceptibility testing for Mycobacterium tuberculosis in Taiwan.台湾地区结核分枝杆菌药敏试验的熟练度
Int J Tuberc Lung Dis. 2009 Sep;13(9):1142-7.
5
Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.结核分枝杆菌对吡嗪酰胺药敏试验的熟练度:瑞典经验。
Int J Tuberc Lung Dis. 2013 Nov;17(11):1486-90. doi: 10.5588/ijtld.13.0195.
6
Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998.世界卫生组织/国际防痨和肺部疾病联盟超国家参考实验室网络中结核分枝杆菌药敏试验的质量保证计划:1994 - 1998年的五轮能力验证试验
Int J Tuberc Lung Dis. 2002 Sep;6(9):748-56.
7
[The external quality assessment for Mycobacterium tuberculosis drug susceptibility testing by proficiency testing panel to the commercial laboratories].[通过能力验证小组对商业实验室进行结核分枝杆菌药敏试验的外部质量评估]
Kekkaku. 2005 Apr;80(4):349-58.
8
First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China.中国 12 个省份二线抗结核药物药敏检测的首次能力验证。
Int J Tuberc Lung Dis. 2013 Nov;17(11):1491-4. doi: 10.5588/ijtld.13.0275.
9
Results of the external quality assessment of Mycobacterium tuberculosis drug susceptibility testing in Russia, 2005-2007.2005 - 2007年俄罗斯结核分枝杆菌药敏试验的外部质量评估结果
Int J Tuberc Lung Dis. 2009 Oct;13(10):1294-300.
10
Will molecular diagnosis of drug-resistant tuberculosis improve patient outcomes?耐多药结核病的分子诊断能否改善患者预后?
Int J Tuberc Lung Dis. 2012 Jan;16(1):4-5. doi: 10.5588/ijtld.11.0419.

引用本文的文献

1
Genetic diversity and transmission pattern of multidrug-resistant tuberculosis based on whole-genome sequencing in Wuhan, China.基于全基因组测序的中国武汉耐多药结核病的遗传多样性和传播模式
Front Public Health. 2025 Jan 28;13:1442987. doi: 10.3389/fpubh.2025.1442987. eCollection 2025.
2
Targeted next-generation sequencing - a promising approach in the diagnosis of Mycobacterium tuberculosis and drug resistance.靶向二代测序——一种用于诊断结核分枝杆菌及耐药性的有前景的方法。
Infection. 2025 Jun;53(3):967-979. doi: 10.1007/s15010-024-02411-w. Epub 2024 Oct 17.
3
Proficiency of phenotypic drug susceptibility testing for Mycobacterium tuberculosis in China, 2008-2021.
2008-2021 年中国结核分枝杆菌表型药敏检测的熟练程度。
PLoS One. 2024 May 29;19(5):e0304265. doi: 10.1371/journal.pone.0304265. eCollection 2024.
4
A comparative study of MassARRAY and GeneXpert assay in detecting rifampicin resistance in tuberculosis patients' clinical specimens.对结核患者临床标本中利福平耐药性检测的MassARRAY和GeneXpert检测法的比较研究。
Front Microbiol. 2024 Feb 7;15:1287806. doi: 10.3389/fmicb.2024.1287806. eCollection 2024.
5
Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy.表型与基因型不一致的利福平药敏试验在结核病中的诊断价值:对诊断准确性的影响。
Microbiol Spectr. 2024 Jan 11;12(1):e0163123. doi: 10.1128/spectrum.01631-23. Epub 2023 Nov 20.
6
Analysis of Drug-Resistance Characteristics and Genetic Diversity of Multidrug-Resistant Tuberculosis Based on Whole-Genome Sequencing on the Hainan Island, China.基于中国海南岛全基因组测序的耐多药结核病耐药特征及遗传多样性分析
Infect Drug Resist. 2023 Sep 4;16:5783-5798. doi: 10.2147/IDR.S423955. eCollection 2023.
7
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.结核分枝杆菌分子药物耐药检测的临床意义:2023 年 TBnet/RESIST-TB 共识声明。
Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28.
8
Use of Whole-Genome Sequencing to Predict Complex Drug Resistance from Early Positive Liquid Cultures.使用全基因组测序技术从早期阳性液体培养物预测复杂药物耐药性。
Microbiol Spectr. 2022 Apr 27;10(2):e0251621. doi: 10.1128/spectrum.02516-21. Epub 2022 Mar 21.
9
Rapid Detection of Ethambutol-Resistant from Sputum by High-Resolution Melting Analysis in Beijing, China.在中国北京通过高分辨率熔解分析从痰中快速检测耐乙胺丁醇情况
Infect Drug Resist. 2020 Oct 20;13:3707-3713. doi: 10.2147/IDR.S270542. eCollection 2020.
10
Detection of tuberculosis laboratory cross-contamination using whole-genome sequencing.使用全基因组测序检测结核病实验室交叉污染。
Tuberculosis (Edinb). 2019 Mar;115:121-125. doi: 10.1016/j.tube.2018.10.012. Epub 2019 Mar 9.